Koen Hussaarts

Koen Hussaarts is a Researcher at Erasmus MC in the Department of General Practice, actively involved in clinical pharmacology and pharmaceutical sciences. His research focuses on pharmacokinetics, drug interactions, and their impact on cancer therapy, particularly in breast and lung cancers.

Research Interests: His primary research areas include pharmacokinetics, drug-drug and drug-food interactions, personalized medicine in oncology, and optimization of anticancer drug efficacy. He investigates how concomitant medications (e.g., cimetidine, probenecid, esomeprazole) and dietary components (e.g., cow's milk) affect the absorption and metabolism of key oncology drugs such as tamoxifen, endoxifen, erlotinib, and sorafenib.

The recent trends in his publications indicate a strong emphasis on translational clinical studies that bridge pharmacological principles with real-world patient outcomes. His work often involves crossover pharmacokinetic trials and aims to improve the safety and effectiveness of cancer treatments through better understanding of drug interactions.

• No scientific awards were mentioned in the provided text.

Advising and Grants: There is no public information available regarding students supervised or grants received by Koen Hussaarts. However, his collaborative research projects suggest active participation in multidisciplinary teams, often under the supervision or collaboration of senior investigators such as Prof. Rob Mathijssen.

Labs and Teams: Koen Hussaarts is part of a research group within Erasmus MC focused on clinical pharmacology and oncology, particularly investigating pharmacokinetic variability and drug interactions in cancer patients. He collaborates extensively with clinical and pharmacological researchers across departments, contributing to studies involving precision dosing and therapeutic drug monitoring.